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Abstract: Background: Male breast cancer (BC) is a distinct neoplasm with low but rising incidence,
frequently diagnosed as advanced stage disease. Considering the relevance of altered homologous
recombination repair (HRR) in male BC, we aimed to explore the biomarker potential of aberrant
promoter methylation of ATM, BRCA1, PALB2, RAD51B, and XRCC3. Methods: Formalin-fixed
paraffin-embedded (FFPE) tissue samples from 128 male BC patients, paired adjacent normal
tissue and 19 gynecomastia cases were collected and assessed by quantitative methylation-specific
PCR (qMSP). Non-parametric tests were used to compare methylation levels between tumor and
non-tumor samples and to seek for associations with clinicopathological variables. Results: Only
RAD51B and XRCC3 disclosed significant differences between tumor and gynecomastia (p < 0.0001
and p = 0.020, respectively). Assembled in a panel, RAD51B and XRCC3 promoter methylation
discriminated male BC from gynecomastia with 91.5% sensitivity, 89.5% specificity, and 91.2%
accuracy. Moreover, promoter methylation levels were lower in paired non-tumor tissues, comparing
to tumor samples. No associations were found between epigenetic alterations and clinicopathological
features, as well as with RAD51 and XRCC3 immunoexpression and methylation levels. Conclusion:
Quantitative promoter methylation of RAD51B and XRCC3 constitutes a promising and accurate
biomarker for male BC. Validation in larger series and in liquid biopsies is warranted to confirm its
usefulness in detection and monitoring settings.
Keywords: male breast cancer; epigenetics; homologous recombination DNA repair; detection
1. Introduction
Male breast carcinoma (BC) is a multifactorial neoplasm lacking specific guidelines for detection,
therapy and surveillance. Although it constitutes a rare entity, comparatively to its female counterpart,
incidence has been rising over the last decades [1,2]. Furthermore, advanced stage disease is rather
common at diagnosis [1]. Although several genetic, hormonal, and environmental risk factors have been
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acknowledged, an in-depth understanding of the biologic peculiarities of male breast carcinogenesis is
clearly lacking [3].
The process of carcinogenesis is complex, resulting from the accumulation of multiple genetic
and epigenetic alterations [4]. The best characterized epigenetic change in cancer consists on altered
methylation of CpG dinucleotides, impacting on genome stability and regulation of gene expression [5].
Aberrant methylation, occurring mostly at gene promoter regions, is associated with gene transcription
repression [5]. This alteration is among the most common and earliest events involved in cancer
initiation and promotion, being easily measured [6].
Homologous recombination repair (HRR) is a major surveillance mechanism in the preservation
of genome integrity, acting in repair of DNA double-strand breaks, which occur during replication [7].
BRCA2, the most common high penetrance susceptibility gene for male BC, but also ATM, BRCA1,
PALB2, RAD51, and RAD51 paralogs play important roles in HRR pathway [8]. RAD51 paralogs
encode for proteins that structurally resemble RAD51 and congregate in vivo into three subcomplexes,
comprising BCDX2 (RAD51B, RAD51C, RAD51D, XRCC2), CX3 (RAD51C, XRCC3), and the Shu
complex (SWSAP1, SWS1) [7–12]. Indeed, the balance between BRCA2, RAD51 and RAD51 paralogs
seems to be essential in HRR [8,12,13]. Mutations in HRR genes, either somatic and/ or in the germline
occur in multiple conditions, including hereditary breast and ovarian cancer susceptibility syndromes,
in which there is also increased male BC risk [2,8,14–17]. Nonetheless, HRR deficiency may also be
mediated by DNA repair gene aberrant promoter methylation. Although altered DNA methylation
has been seldom reported in male BC, it might constitute a novel biomarker for disease detection and
monitoring, allowing for more personalized clinical care [4,18–21].
Owing to the relevance of HRR deficiency in male BC and the lack of systematic studies on
altered methylation patterns of HRR genes in this specific context, we aimed to explore the epigenetic
signature of the HRR genes ATM, BRCA1, PALB2, RAD51B, and XRCC3 in a large, well characterized
(clinically and pathologically) series of male BC patients, to identify novel detection, diagnostic and/or
prognostic biomarkers that might perfect clinical management.
Additionally, 19 cases of gynecomastia were added as benign comparative model. Gynecomastia
is the most common benign disease in male breast and shares risk factors with male BC, including high
estrogen levels [18,22]. However, gynecomastia is not considered by itself a risk factor for male BC [22].
2. Results
2.1. Clinical and Pathological Data
This study included 128 male BC, matched normal tissues (66 normal breast tissue and 62 axillary
lymph nodes) and 19 patients with gynecomastia. Detailed clinicopathologic characterization of the
male BC cases is provided in Table 1. The mean age of patients with breast cancer at diagnosis was
66.7 years (range: 37–87 years). About 20% of the male BC patients had a familial history (FH) of breast
cancer. Germline BRCA1 mutations were not found in this series. Germline BRCA2 mutations were
found in 12 patients (32.4%). Ten (83.3%) of these 12 patients had a FH of breast cancer. Six patients
(4.7%) had bilateral carcinoma and 20 patients (15.6%) had non-breast primary neoplasm (NBPN),
most of them (eight patients—40%) corresponding to prostate cancer. Germline BRCA mutations
were evaluated in 12 patients with NBPN and BRCA2 was identified in four (33.3%) of these patients,
all with a FH of BC (Table 2).
Patients with gynecomastia were younger, with a mean age of 34.3 years (range: 16–69 years). None
of the patients with gynecomastia had FH of breast cancer. Twelve cases were bilateral. Five patients
had NBPN, two of which were prostate carcinomas. One patient with gynecomastia and prostate
carcinoma harbored a germline BRCA2 mutation.
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Table 1. Clinicopathological characteristics of male breast cancer patients.
Characteristics Number Number (%)
Age (years)
12837–69 67 (52.3%)
≥70 61 (47.7%)
Familial history (FH) of breast cancer
128No 102 (79.7%)
Yes 26 (20.3%)
Bilateral breast cancer
128No 122 (95.3%)
Yes 6 (4.7%)
Non-breast primary neoplasms (NBPN)
128No 108 (84.4%)
Yes 20 (15.6%)
Tumor size (pT)
128
pTis 8 (6.2%)
pT1 31 (24.2%)
pT2 43 (33.6%)
pT3 2 (1.6%)
pT4 44 (34.4%)
Axillary nodal status (pN)
128pN0 60 (46.9%)
pN1 68 (53.1%)
Distant metastasis (M)
128M0 122 (95.3%)
M1 6 (4.7%)
Anatomic stage (AS)
128
0 8 (6.2%)
I 23 (20%)
II 47 (36.7%)
III 43 (33.6%)
IV 7 (5.5%)
Histological type (HT)
120 1Invasive no special type (NST) 112 (93.3%)
Other invasive subtypes 8 (6.7%)
Histological grade (G)
120 1
G1 20 (16.7%)
G2 74 (61.7%)
G3 26 (21.6%)
1 Excluding eight in situ carcinomas.
2.2. Gene Promoter Methylation Levels
ATM, BRCA1, PALB2, RAD51B, and XRCC3 promoter methylation levels were evaluated in paired
tumor, normal tissue, and adjacent lymph nodes, and in gynecomastia tissue samples. Only RAD51B
and XRCC3 disclosed statistically significant differences between tumor and gynecomastia tissues,
with higher methylation levels observed in gynecomastia tissue samples (Table 3, Figure 1).
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Table 2. Molecular characteristics and follow-up of male breast cancer patients.
Characteristics Number Number (%)
Germline BRCA2 mutations
37Indeterminate 25 (67.6%)
Positive 12 (32.4%)
Estrogen receptor (ERα) status
128Positive 125 (97.7%)
Negative 3 (2.3%)
Progesterone receptor (PR) status
120 1Positive 97 (81%)
Negative 23 (19%)
ERBB2 (IHC and ISH) status
120 1Negative 111 (92.5%)
Positive 9 (7.5%)
Ki67 immunoreactivity
120 1Low 77 (64.2%)
High 43 (35.8%)
Clinically defined subtypes
120 1
Luminal A-like 44 (36.7%)
Luminal B-like 64 (53.3%)
HER2-like 9 (7.5%)
Triple negative 3 (2.5%)
Follow-up
128Died of disease 40 (31.3%)
1 Excluding eight in situ carcinomas.
Table 3. Genes’ methylation levels p values comparing tumor and gynecomastia tissues.
Gene p Value
ATM 0.749
BRCA1 0.289
PALB2 0.436
RAD51B <0.0001
XRCC3 0.020
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Furthermore, XRCC3 promoter methylation levels were lower in normal adjacent tissue comparing
to tumor tissue (p = 0.002), whereas RAD51B promoter methylation levels were higher in tumor samples,
although not reaching statistical significance (p = 0.968) (Figure 2). No differences were depicted for
the remainder genes.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 12 
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2.3. Biomarker Performance
The gene promoters that showed statistically significant differences between tumor and
gynecomastia samples (RAD51B and XRCC3) were evaluated as potential biomarkers for male
BC. Individually, RAD51B displayed over 80% sensitivity and specificity, whereas XRCC3 correctly
identified 43.4% of the tumor samples with 94.7% specificity (Table 4).
Table 4. Biomarker performance detection of RAD51B and XRCC3 hypomethylation levels in tissue samples.
Validity Estimates RAD51B XRCC3
Sensitivity % 82.9 43.4
Specificity % 94.7 94.7
Accuracy % 84.7 51.2
hen the t o genes ere asse bled in a panel, sensitivity increased to 91.5 , ith 89.5
specificity and 91.2 accuracy for identification of ale B vs. gyneco astia (Table 5, Figure 3).
able 5. i ar er erf r a ce etecti f 51 a 3 et lati e e a el le els
i tiss s l s.
Validity Estimates RAD51B XRCC3
Sensitivity % 91.5
Specificity % 89.5
Accuracy % 91.2
No statistically significant associations between epigenetic alterations in the tested HRR genes
and clinicopathological parameters were depicted, either in male BC or gynecomastia cases.
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2.4. Immunohistochemistry
Almost all cases depicted positive cytoplasmatic staining, whereas RAD51 and XRCC3 nuclear
staining was only observed in one case (Table 6). RAD51 and XRCC3 nuclear and cytoplasmatic
staining was also observed in one male BC patient No associations were found between RAD51 and
XRCC3 immunoexpression and methylation levels (Figure 4).
Table 6. AD51 and XRCC3 immunohistochemical expression in Male BC
Immunoexpression RAD51 (Number of Cases) XRCC3 (Number of Cases)
Positive cytoplasmatic 33 (all) 32
Positive nuclear and cytoplasmatic 1 1
Negative nuclear and cytoplasmatic 0 1
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RAD51 and XRCC3 exhibited consistent staining patterns both in gynecomastia and female
breast normal tissue: Intense positive nuclear d cytoplasmatic stai ing was found for RAD51 in
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all samples, whereas negative nuclear staining and a weak cytoplasmatic staining was observed
for XRCC3 (Figure 5). Nonetheless, no inverse correlation was found between methylation and
imunoexpression status.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 12 
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3. Discussion
Male BC is a multifactorial and distinctive neoplasia with low, but rising, incidence, requiring a
personalized approach and warranting optimal care [1,23]. To achieve this aim, detailed knowledge of
genetic and epigenetic alterations, as well as of other specific characteristics of BC in the male gender
are mandatory [23]. Population-based mammographic screening in males has no role considering
the rarity of male BC, although it may be useful in selected high-risk groups [1,24]. In current
clinical practice, male BC is diagnosed by mammography or ultrasonography and confirmed by
core biopsy, which is always performed following a suspicious clinical examination and frequently
at advanced disease stage [1]. Furthermore, specific biomarkers that might assist in early disease
detection, diagnosis, and prognostication are clearly lacking and constitute an unmet need. We, thus,
assessed the methylation status of five genes (ATM, BRCA1, PALB2, RAD51B, and XRCC3) involved in
HRR (which is deficient in a large proportion of male BC cases) looking for biomarkers that might be
useful for clinical management.
Notwithstanding the biological peculiarities of male BC, the uselessness of mammographic
screening due to low incidence rates, the high incidence of gynecomastia that may have overlapping
clinical presentation, the particular anatomic characteristics of the male breast, the absence of
publicly-available information about the disease, the prevalence in old age groups and the fact
that males are less likely to report symptoms that would guide to an early diagnosis, contribute to the
significant number of advanced stage disease at diagnosis and, consequently, the high mortality rates
of male BC [25]. Indeed, in this cohort, 39.1% of the patients presented at stages III and IV and 31.3%
died of disease, underlining the importance of early diagnosis. Furthermore, evidence of significant
hereditary predisposition was found in this cohort (FH of breast cancer, BRCA2 mutations and NBPN,
in 20.3%, 32.4%, and 15.5% of cases, respectively) which is line with published literature [26,27].
Furthermore, the clinical and pathological characteristic of the patient population are also similar to
those previously published [3,21,28], which further validates our dataset.
Although the acquisition of epigenetic alterations, in general, and aberrant DNA methylation, in
particular, is widely acknowledged as an early and relevant event in tumorigenesis [29], these have been
seldom reported and with different purposes, in male BC [4,18–21]. Kornegoor et al., examined promoter
methylation of 25 genes in 108 male BCs using methylation specific multiplex ligation dependent
probe amplification and concluded that promoter methylation was common in male BC and that high
methylation status correlated with aggressive phenotype and poor outcome [18]. Subsequently, Pinto
et al. found different expression patterns in male and female familial BC in a set of 27 familial BC cases,
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using qMSP [19]. Johanssen et al. performed a genome-wide methylation profiling of 47 male BC,
underscoring the heterogeneity of this entity and suggesting that male BC should not be defined using
conventional criteria applied to female breast cancer [20]. Using methylation-sensitive high resolution,
Deb et al. assessed a panel of 10 genes in 60 male BCs, concluding that BRCA2-associated male BC
was characterized by high gene methylation and that the average methylation index might be a useful
prognostic marker [4]. Finally, Rizzolo et al. assessed promoter methylation in 69 male BC patients
and concluded that alterations in methylation patterns were common in BC and might identify specific
subgroups related to BRCA1/2 mutation status and some clinicopathologic parameters [21].
Among the five gene promoters tested, only two - RAD51B and XRCC3—disclosed statistically
significant differences between tumor and gynecomastia tissue samples, whereas ATM, BRCA1,
and PALB2 did not. Nevertheless, because only 19 gynecomastia tissues were included in this study,
the results must be interpreted with caution and further validation using an independent cohort is
required. Furthermore, RAD51B and XRCC3 promoter levels were higher in tumor tissues compared
to normal breast or lymph node, although with statistical significance for XRCC3, only. Globally,
these results are in line with those of Kornegoor et al., which found that ATM and BRCA1 promoter
methylation did not seem to play a key role in male BC genesis [18]. Interestingly, RAD51B and XRCC3
promoter methylation has been reported in association with the inflamed phenotype of squamous
cell carcinomas of the head and neck, lung, and cervix, warranting further investigation as predictive
biomarkers of response to immunotherapy [30].
Gynecomastia is a common benign proliferation of the breast that shares with male BC the risk
factors related to high estrogen levels and its discrimination from BC is clinically challenging, being
not considered a risk factor for male BC [22]. Thus, it was selected as control for determining the
biomarker performance of gene promoter methylation as this constitutes a clinical scenario in which
specific biomarkers might aid in differential diagnosis and monitoring. Remarkably, the methylation
panel combining RAD51B and XRCC3 accurately discriminated male BC from gynecomastia, in
tissue samples. This might prove useful in the diagnostic context of biopsies with limited tissue
representativeness but translation into monitoring scenarios requires the validation of this performance
in liquid biopsies. Nevertheless, it should be emphasized that this gene methylation panel constitutes
the first discriminative biomarker in this setting.
Interestingly, normal breast tissues disclosed RAD51B and XRCC3 promoter methylation, although
with lower median promoter methylation levels compared to BC, suggesting the existence of a
cancerization field effect. This phenomenon reflects the susceptibility of normal tissue to undergo
early genetic and epigenetic alterations leading to tumor development [31]. Field cancerization was
hypothesized to explain the development of multifocal areas of premalignant change, multiple primary
tumors and local recurrence [32] and more recent studies demonstrate that aberrant DNA methylation
patterns, either hyper- or hypomethylation, are potential biomarkers of field cancerization and may
be useful for risk stratification [33]. Surprisingly, however, higher RAD51B and XRCC3 promoter
methylation levels were disclosed in gynecomastia comparing to male BC. This finding might be
related with proliferation, high estrogen levels or other yet unknown risk factors. To understand the
biological consequences of these observations, expression analysis of those genes was performed,
but no significant associations were disclosed between methylation levels and RAD51 and XRCC3
expression for gynecomastia and BC lesions, as well as for adjacent normal breast tissue. However,
the only antibody available is not specific for RAD51B protein. Moreover, promoter methylation
acts in concert with other epigenetic mechanisms (e.g., histone post-translational modifications and
chromatin remodeling) to achieve effective gene silencing. Thus, although RAD51B and XRCC3
promoter methylation levels might be higher in gynecomastia, histone-related factors might preclude
effective gene silencing, contrarily to BC. Notwithstanding the elusive biological significance of
this finding, RAD51B and XRCC3 promoter methylation stand as candidate biomarkers for male
BC, requiring further exploitation, namely in liquid biopsies by analyzing circulating cell-free DNA
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methylation in plasma or serum samples, which could better represent tumor heterogeneity and allow
for a minimally-invasive strategy for BC detection.
4. Materials and Methods
4.1. Patients and Samples Collection
A cohort of 128 male BC patients, diagnosed and treated at the Portuguese Oncology Institute
of Lisbon (Lisbon, Portugal), between 1978 and 2018 were enrolled, after informed consent. Routine
sampling for standard pathological examination by H&E and immunostaining was performed, allowing
for tumor classification, grading and staging [34]. A representative formalin-fixed, paraffin-embedded
(FFPE) tumor tissue sample was made available for molecular analyses. The corresponding adjacent
normal breast tissue and lymph nodes were also included in the study, as controls. For comparison
purposes, 19 cases of gynecomastia were used. Patient data, including age, family history, tumor
bilaterality, presence of non-breast primary neoplasms, information about distant metastasis and
follow-up were obtained from clinical records. Germline mutational BRCA2 status was evaluated in
37 cases of male BC and in one case of gynecomastia, as previously described [25]. This study was
approved by the Ethics Committee of Portuguese Oncology Institute of Lisbon (UIC/859 in 12/11/2013).
4.2. DNA Extraction and Sodium-Bisulfite Modification
Areas of interest (breast cancer, normal breast and gynecomastia) were delimited in H&E slides by
a dedicated Pathologist (S.A.), macrodissected from 10 µm tissue sections, deparaffinized with xylene
(VWR, Radnor, PA, USA) and rehydrated using 100% ethanol (Merck Millipore, Burlington, MA, USA).
DNA was extracted using the FFPE RNA/DNA Purification Plus Kit (Norgen Biotek, Thorold, ON,
Canada) according to the manufacturer’s recommendations. DNA samples were eluted in 20 µL of
sterile distilled water and stored at −20 ◦C until further use. DNA was quantified using the Qubit 4
Fluorometer (Invitrogen, Carlsbad, CA, USA), using the manufacturer’s recommendations.
Sodium-bisulfite modification was performed in all samples using the EZ DNA Methylation-GoldTM
(Zymo Research, Orange, CA, USA) following the manufacturer’s recommendations. 150 ng of extracted
DNA were used and eluted in 60 µL of sterile distilled water. Additionally, 1000 ng of CpGenomeTM
Universal Methylated DNA (Millipore, Temecula, CA, USA) was sodium-bisulfite converted for control
purposes and eluted in 40 µL of sterile distilled water. All sodium-bisulfite converted DNA was stored at
−80 ◦C until further use.
4.3. Quantitative Methylation-Specific PCR (qMSP)
ATM, BRCA1, PALB2, RAD51B, and XRCC3 (Supplementary Figure S1) promoter methylation
levels were assessed by qMSP, using β-Actin as a reference gene. The reactions were carried out in
384-well plates using the LightCycler 480 Instrument (Roche Diagnostics, Manhaeim, Germany) and
the sodium-bisulfite modified DNA was used as a template. The primers’ volumes and conditions
used for each gene are listed in Supplementary Table S1. Per well, 2 µL of sodium-modified
DNA and 5 µL of Xpert Fast SYBR (GRiSP, Porto, Portugal) were added. All samples were run in
triplicate. In order to generate a standard curve for DNA relative quantification and plate efficiency
calculation, the sodium-bisulfite modified CpGenomeTM Universal Methylated DNA was subjected
to serial dilutions (5× dilution factor). Efficiency values above 90% were considered for each plate.
Relative methylation levels were obtained by calculating the ratio between the methylation levels of
each gene and the respective value of β-Actin, multiplying by 1000 for easier tabulation.
4.4. Immunohistochemistry
Immunohistochemical staining was performed on 4-µm-thick, formalin-fixed, paraffin-embedded
tissue sections from 3 tissue microarrays (TMAs) that included 33 male BC cases and 10 gynecomastia
cases and one TMA including 22 normal female breast tissue (cases retrieved from patients with age
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range from 40 to 70 years-old). Slides were stained on the BenchMark ULTRA IHC/ISH Automatic
staining platform (Ventana Medical Systems) with anti-human XRCC3 (dilution 1:20, for 40 min;
pretreatment ULTRA CC1-72 min, catalogue number SAB4503092, Sigma), anti-human RAD51 antibody
(dilution 1:700 for 40 min; pretreatment ULTRA CC1-48 min, catalog number SAB1406364, Sigma),
with appropriate positive and negative controls samples. Antigen detection was performed using
OptiView DAB IHC Detection Kit (Ventana Medical Systems) with diaminobenzidine as the chromogen
to detect antigen expression. Tissue sections were counterstained with Mayer's hematoxylin.
4.5. Statistical Analysis
Non-parametric tests were used to compare the methylation levels between tumor and
non-tumorous samples and to assess associations with clinicopathological variables (Kruskall–Wallis
test for three or more groups, followed by pairwise comparisons using Mann–Whitney U test
with Bonferroni’s correction, when applicable, and Wilcoxon signed-rank test for paired samples).
Correlations between age and genes’ methylation levels were evaluated by Spearman’s nonparametric
test. Receiver operating characteristic (ROC) curve analysis was performed and the validity estimates
(sensitivity, specificity, and accuracy) were calculated to assess biomarker performance. Tumor samples
of patients subjected to neoadjuvant therapy were not considered for this analysis. Samples were
categorized as methylated (positive) or unmethylated (negative) based on the cut-off determined by
ROC curve analysis corresponding to the highest sensitivity and specificity (Youden’s J index) [35].
5. Conclusions
In this study we demonstrated that promoter methylation levels of RAD51B and XRCC3 differ
between male BC and gynecomastia tissues, suggesting its usefulness, in a panel, as male BC biomarkers.
Further analyses in liquid biopsies are mandatory to assess the potential of this panel for early detection,
in at-risk populations, and disease monitoring.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/8/2715/s1.
Supplementary Table S1: Primers sequences, annealing temperature and final concentration in the PCR reaction.
Supplementary Figure S1: Gene location of the CpG islands and amplicons for ATM, BRCA1, PALB2, RAD51B and
XRCC3. Blue arrow represents the gene promoter; Yellow boxes represent CpG islands; Red arrows represent the
primers and amplicon; Numbers below the yellow boxes and next to the red arrows stand for the gene coordinates
based on Human GRCh38/hg38 Assembly.
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